GlassScriptPhysician profile
Anthony Kent
NPI 1942685441
$58,322.88
in general payments reported to CMS, 2019-2025
26 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $231 · 2023: $995 · 2024: $32K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $4,904 · Travel and Lodging: $2,037 · Consulting Fee: $1,600 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,530.00 |
| Food and Beverage | $4,904.35 |
| Travel and Lodging | $2,037.18 |
| Consulting Fee | $1,600.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29,639.17 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $23,711.98 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $2,347.05 | 2022-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $426.93 | 2022-2025 | |
| Travere Therapeutics, INC. | $309.79 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $215.02 | 2022-2025 | Korsuva, Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $202.83 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $180.56 | 2023 | Lupkynis |
| Amgen INC. | $151.41 | 2023-2025 | Tavneos, Parsabiv |
| Vifor Pharma, INC. | $139.30 | 2023-2025 | Veltassa |
| Ardelyx, INC. | $136.63 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $128.15 | 2023-2025 | Gattex |
| Otsuka America Pharmaceutical, INC. | $98.41 | 2023-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $85.97 | 2024-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $85.92 | 2024-2025 | Tarpeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $78.43 | 2023-2025 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $64.47 | 2024-2025 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $57.07 | 2024 | Jynarque |
| Daiichi Sankyo INC. | $56.88 | 2023-2024 | Injectafer |
| Kyowa Kirin, INC. | $54.33 | 2024-2025 | Crysvita |
| Novo Nordisk INC | $46.84 | 2023-2025 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $31.45 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.34 | 2025 | Empaveli |
| Cormedix INC. | $21.33 | 2025 | Defencath |
| Akebia Therapeutics INC | $19.92 | 2025 | Vafseo |
| Daxor Corporation | $11.70 | 2024 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.